Aristo Bio-Tech receivables rose Rs 59.11 crore in first half
Key highlights
- Trade receivables rose Rs 59.11 crore to Rs 113.84 crore at September 30, 2026.
- Inventory fell Rs 29.01 crore to Rs 34.20 crore during the half year.
- Trade payables increased Rs 25.51 crore to Rs 96.36 crore at September 30, 2026.
- Net cash from operating activities was Rs 2.42 crore in the half year ended September 30, 2026.
powered by IRIS

Aristo Bio-Tech and Lifescience Limited reported a Rs 59.11 crore increase in trade receivables in the half year ended September 30, 2026, exceeding a Rs 29.01 crore inventory release and limiting net operating cash flow to Rs 2.42 crore. Trade receivables reached Rs 113.84 crore, against Rs 54.73 crore on March 31, 2026.
Know Aristo Bio-Tech & Lifescience inside out
Results, valuation, peers and who's buying, in one view.
How did Aristo Bio-Tech's working capital change?
Aristo Bio-Tech's working-capital movement was led by the Rs 59.11 crore receivables build-up during the six months ended September 30, 2026. Trade receivables rose to Rs 113.84 crore from Rs 54.73 crore at March 31, 2026, and the cash-flow statement records a Rs 59.11 crore outflow under the increase in trade receivables.
Inventory moved in the opposite direction, falling to Rs 34.20 crore at September 30 from Rs 63.21 crore six months earlier. The Rs 29.01 crore reduction released cash, but it was less than half the receivables movement. Short-term loans and advances also increased to Rs 13.43 crore from Rs 9.18 crore, consuming Rs 4.24 crore of cash.
Other current assets generated a Rs 15.97 lakh cash inflow in the September half year, while their balance declined to Rs 25.16 lakh from Rs 41.13 lakh. The cash-flow statement therefore reports a combined Rs 34.19 crore outflow from current assets other than cash, following the inventory release, the receivables increase and the movement in loans and advances.
What offset the increase in Aristo Bio-Tech receivables?
Aristo Bio-Tech partly offset the receivables outflow through lower inventory and higher current liabilities. Trade payables increased by Rs 25.51 crore to Rs 96.36 crore at September 30, 2026, from Rs 70.85 crore at March 31, 2026. The cash-flow statement separately records a Rs 25.51 crore increase in trade payables.
Dues to creditors other than micro and small enterprises rose to Rs 90.72 crore from Rs 64.90 crore, an increase of Rs 25.82 crore. In contrast, dues to micro and small enterprises declined to Rs 5.64 crore from Rs 5.95 crore, a reduction of Rs 30.58 lakh. These two categories together produced the Rs 96.36 crore trade-payables closing balance.
Short-term borrowings rose by Rs 1.04 crore to Rs 28.81 crore, while other current liabilities increased by Rs 3.37 crore to Rs 4.94 crore. Short-term provisions fell by Rs 1.47 crore to Rs 1.81 crore. Taken together, movements in current liabilities provided Rs 28.46 crore of cash in the September half year, compared with Rs 7.90 crore in the year ended March 31, 2026.
The Rs 29.01 crore inventory release and the Rs 28.46 crore contribution from current liabilities did not fully offset the Rs 59.11 crore receivables increase and Rs 4.24 crore rise in short-term loans and advances. That arithmetic helps explain why cash generated from operations was Rs 4.11 crore despite profit before tax of Rs 6.60 crore.
Got a follow-up? Ask IRIS
How much operating cash did Aristo Bio-Tech generate?
Aristo Bio-Tech generated Rs 2.42 crore of net cash from operating activities in the half year ended September 30, 2026. Cash generated from operations before tax-related deductions was Rs 4.11 crore, compared with Rs 11.37 crore for the year ended March 31, 2026; the company disclosed periods of six months and 12 months, respectively.
Profit before tax and extraordinary items was Rs 6.60 crore for the September 2026 half year, compared with Rs 5.54 crore for the half year ended September 30, 2025. Revenue from operations was Rs 198.24 crore in the latest half year, below Rs 256.45 crore in the corresponding half year of 2025, while profit before tax increased by Rs 1.05 crore.
In reconciling profit to cash generated from operations, the company added back Rs 1.57 crore of depreciation and Rs 1.76 crore of finance cost. It deducted Rs 8.35 lakh of interest income. The reported profit before tax of Rs 6.60 crore was also higher than Rs 4.15 crore in the six months ended March 31, 2026.
Income tax paid was Rs 1.46 crore and the deferred-tax adjustment was Rs 23.72 lakh in the September 2026 half year, resulting in Rs 2.42 crore of net operating cash. For the year ended March 31, 2026, income tax paid was Rs 2.58 crore and net operating cash was Rs 8.85 crore.
What do Aristo Bio-Tech's reported balances show?
Aristo Bio-Tech's September 30 balance sheet shows receivables of Rs 113.84 crore as its largest stated current-asset line, compared with inventory of Rs 34.20 crore and cash and cash equivalents of Rs 2.55 crore. Cash and cash equivalents declined by Rs 8 lakh from Rs 2.63 crore at March 31, matching the reported net decrease in cash during the half year.
On the funding side, short-term borrowings stood at Rs 28.81 crore and long-term borrowings were Rs 7.77 crore on September 30, 2026. Long-term borrowings increased by Rs 14.12 lakh over the half year. Interest expense was Rs 1.49 crore and finance cost was Rs 14.45 lakh in the financing-cash-flow section.
Reserves and surplus increased to Rs 42.20 crore from Rs 37.30 crore, while paid-up equity share capital remained Rs 6.81 crore. Net profit for the September 2026 half year was Rs 4.90 crore, compared with Rs 4.17 crore in the half year ended September 30, 2025. Basic and diluted earnings per share were both Rs 7.20, against Rs 6.12 a year earlier.
Total assets and total equity and liabilities were each Rs 188.95 crore at September 30, 2026, up from Rs 155.22 crore at March 31, 2026. The Rs 33.74 crore balance-sheet increase occurred alongside the Rs 59.11 crore rise in receivables, the Rs 29.01 crore inventory reduction and the Rs 25.51 crore increase in trade payables.
Conclusion
Aristo Bio-Tech's September 2026 half-year disclosure identifies receivables as the main call on working capital, with a Rs 59.11 crore increase exceeding the Rs 29.01 crore inventory release. Higher trade payables contributed Rs 25.51 crore, but net operating cash was Rs 2.42 crore after Rs 1.46 crore of income tax paid and a Rs 23.72 lakh deferred-tax adjustment.
What remains unresolved is whether the Rs 113.84 crore receivables balance converts into cash and how the Rs 96.36 crore trade-payables balance develops. The disclosed September 30, 2026 results were unaudited, subject to the statutory auditor's limited review, and were approved by the board on November 14, 2026.


